JNJ-70033093
Sponsors
Janssen - Cilag International, Janssen Research & Development, LLC
Conditions
Acute Coronary SyndromeAcute Ischemic Stroke and High-Risk Transient Ischemic AttackAtrial FibrillationHealthy
Phase 1
A Study of JNJ-70033093 and Digoxin in Healthy Participants
CompletedNCT04206488
Start: 2020-01-09End: 2021-06-09Updated: 2025-03-30
A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants
CompletedNCT04223349
Start: 2020-01-10End: 2020-04-08Updated: 2025-04-27
A Study of JNJ-70033093 in Healthy Participants
CompletedNCT04448964
Start: 2020-06-26End: 2020-11-14Updated: 2025-03-30
A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants
CompletedNCT04569695
Start: 2021-03-08End: 2021-12-16Updated: 2025-03-30
Phase 3
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
RecruitingCTIS2022-501176-26-00
Start: 2023-08-04Target: 6471Updated: 2025-12-29
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
RecruitingCTIS2022-501418-69-00
Start: 2023-11-21Target: 8535Updated: 2025-12-08
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation
Active, not recruitingCTIS2022-501419-15-00
Start: 2023-08-23Target: 8867Updated: 2025-10-29